Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial.
Breast Cancer Res TreatSep 16, 2026 (epub)
F Schochter, T W P Friedl, H Schäffler et al.
✦ AI-curated · Sources linked
In 30 seconds
The phase II DETECT IVb trial evaluated the efficacy and safety of eribulin in patients with HER2-negative advanced breast cancer. The study found a median progression-free survival (PFS) of 4.6 months and overall survival (OS) of 13.4 months. Notably, 34.7% of patients with circulating tumor cell (CTC) clearance at first follow-up experienced significantly improved PFS.
Key findings
- Median progression-free survival was 4.6 months.
- Overall survival was 13.4 months.
- Patients with CTC-clearance at first follow-up had improved PFS (p = 0.043).
- CTC-clearance at treatment end also correlated with better PFS (p = 0.015).
Why it matters
This study reinforces eribulin's role as an effective treatment for high-risk HER2-negative metastatic breast cancer and highlights the potential of CTC dynamics as an early biomarker for treatment response.